Insulet - PODD Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PODD shares.
View PODD analyst ratings or view top-rated stocks.

13 brokerages have issued 1-year target prices for Insulet's shares. Their PODD share price forecasts range from $245.00 to $345.00. On average, they anticipate the company's stock price to reach $312.08 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $294.39 at the start of the year. Since then, PODD shares have decreased by 2.8% and is now trading at $286.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PODD earnings forecast.

Insulet will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, November, 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, beating the consensus estimate of $0.17 by $0.28. The medical instruments supplier earned $340.80 million during the quarter, compared to analyst estimates of $311.84 million. Insulet had a net margin of 1.35% and a trailing twelve-month return on equity of 18.19%.

Insulet updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $341.55 million-$350.78 million, compared to the consensus revenue estimate of $328.46 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.65%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), AEGON ASSET MANAGEMENT UK Plc (0.27%), Beacon Investment Advisory Services Inc. (0.27%), Scout Investments Inc. (0.22%) and New York State Common Retirement Fund (0.14%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $286.20.

Insulet (NASDAQ:PODD) has a market capitalization of $19.88 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.24 on an earnings per share basis.

The company employs 2,300 workers across the globe.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.